StockMarketWire.com - Orpha drug consultancy Open Orphan said it had sold its remaining shareholding in skin treatment focused Integumen.

Total proceeds of the sale were around £567k.

'The disposal allows the company to focus all its resources on its core strategy of creating a focused orphan drug platform offering a wide range of complementary services to the developers of rare and orphaned drugs,' it said.




Story provided by StockMarketWire.com